ORAMED PHARMACEUTICALS INC.
10-Ks and 10-Qs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended February 28, 2015
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 000-50298
ORAMED PHARMACEUTICALS INC.
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware
|
98-0376008
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(I.R.S. Employer Identification No.)
|
|
Hi-Tech Park 2/4 Givat Ram
PO Box 39098
Jerusalem, Israel
|
91390
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
+ 972-2-566-0001
(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes
x
No
o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes
x
No
o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer
o
|
Accelerated filer
x
|
|
Non-accelerated filer
o
(Do not check if a smaller reporting company)
|
Smaller reporting company
o
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
o
No
x
As of March 31, 2015, there were 10,823,943 shares of the issuer’s common stock, $0.012 par value per share, outstanding.
ORAMED PHARMACEUTICALS INC.
FORM 10-Q
TABLE OF CONTENTS
|
1
|
|
|
1
|
|
|
2
|
|
|
8
|
|
|
8
|
|
|
9
|
|
| ITEM 5 - OTHER INFORMATION | 9 |
|
9
|
As used in this Quarterly Report on Form 10-Q, the terms “we,” “us,” “our” and the “Company” mean Oramed Pharmaceuticals Inc. and our wholly-owned Israeli subsidiary, Oramed Ltd., unless otherwise indicated. All dollar amounts refer to U.S. Dollars unless otherwise indicated.
On February 28, 2015, the exchange rate between the New Israeli Shekel, or NIS, and the dollar, as quoted by the Bank of Israel, was NIS 3.966 to $1.00. Unless indicated otherwise by the context, statements in this Quarterly Report on Form 10-Q that provide the dollar equivalent of NIS amounts or provide the NIS equivalent of dollar amounts are based on such exchange rate.
- i -
ORAMED PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF FEBRUARY 28, 2015
1
ORAMED PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF FEBRUARY 28, 2015
TABLE OF CONTENTS
|
Page
|
|
|
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:
|
|
|
F-2
|
|
|
F-3
|
|
|
F-4
|
|
|
F-5
|
|
|
F-6-F-14
|
ORAMED P
HA
RMACEUTICALS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
U.S. Dollars in thousands (except share and per share data)
|
February 28,
|
August 31,
|
|||||||
|
2015
|
2014
|
|||||||
|
Assets
|
||||||||
|
CURRENT ASSETS:
|
||||||||
|
Cash and cash equivalents
|
$ | 1,102 | $ | 1,762 | ||||
|
Short term deposits
|
16,351 | 18,481 | ||||||
|
Marketable securities
|
695 | 1,047 | ||||||
|
Restricted cash
|
16 | 16 | ||||||
|
Prepaid expenses and other current assets
|
129 | 64 | ||||||
|
Related parties
|
- | 330 | ||||||
|
Grants receivable from the chief scientist
|
2 | 78 | ||||||
|
Total current assets
|
18,295 | 21,778 | ||||||
|
LONG TERM DEPOSITS AND INVESTMENT
|
4,665 | 3 | ||||||
|
AMOUNTS FUNDED IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT
|
7 | 7 | ||||||
|
PROPERTY AND EQUIPMENT, NET
|
13 | 14 | ||||||
|
Total assets
|
$ | 22,980 | $ | 21,802 | ||||
|
Liabilities and stockholders' equity
|
||||||||
|
CURRENT LIABILITIES:
|
||||||||
|
Accounts payable and accrued expenses
|
$ | 570 | $ | 926 | ||||
|
Related parties
|
35 | 47 | ||||||
|
Total current liabilities
|
605 | 973 | ||||||
|
LONG TERM LIABILITIES:
|
||||||||
|
Employee rights upon retirement
|
9 | 9 | ||||||
|
Provision for uncertain tax position
|
27 | 27 | ||||||
| 36 | 36 | |||||||
|
COMMITMENTS
(note 2)
|
||||||||
|
STOCKHOLDERS' EQUITY:
|
||||||||
|
Common stock, $ 0.012 par value (30,000,000 authorized shares; 10,820,193 and 10,102,555 shares issued and outstanding as of February 28, 2015 and August 31, 2014, respectively)
|
129 | 121 | ||||||
|
Additional paid-in capital
|
53,463 | 48,040 | ||||||
|
Accumulated other comprehensive income
|
100 | 452 | ||||||
|
Accumulated loss
|
(31,353 | ) | (27,820 | ) | ||||
|
Total stockholders' equity
|
22,339 | 20,793 | ||||||
|
Total liabilities and stockholders' equity
|
$ | 22,980 | $ | 21,802 | ||||
The accompanying notes are an integral part of the condensed consolidated financial statements.
F-2
ORAMED PH
AR
MACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(UNAUDITED)
U.S. Dollars in thousands (except share and per share data)
|
Six months ended
|
Three months ended
|
|||||||||||||||
|
February 28,
|
February 28,
|
February 28,
|
February 28,
|
|||||||||||||
|
2015
|
2014
|
2015
|
2014
|
|||||||||||||
|
RESEARCH AND DEVELOPMENT EXPENSES, NET
|
$ | 2,438 | $ | 1,424 | $ | 1,136 | $ | 674 | ||||||||
|
GENERAL AND ADMINISTRATIVE EXPENSES
|
1,138 | 930 | 538 | 512 | ||||||||||||
|
OPERATING LOSS
|
3,576 | 2,354 | 1,674 | 1,186 | ||||||||||||
|
FINANCIAL INCOME
|
(65 | ) | (120 | ) | (38 | ) | (74 | ) | ||||||||
|
FINANCIAL EXPENSES
|
22 | 5 | 1 | 3 | ||||||||||||
|
NET LOSS FOR THE PERIOD
|
3,533 | 2,239 | 1,637 | 1,115 | ||||||||||||
|
SUBSEQUENT DECREASE (INCREASE) IN THE FAIR VALUE OF AVAILABLE FOR SALE SECURITIES PREVIOUSLY WRITTEN DOWN AS IMPAIRED
|
9 | (54 | ) | - | (49 | ) | ||||||||||
|
RECLASSIFICATION ADJUSTMENT TO FINANCIAL INCOME OF GAINS
ON AVAILABLE-FOR-SALE SECURITIES
|
- | 44 | - | 26 | ||||||||||||
|
UNREALIZED LOSS (GAIN) ON AVAILABLE FOR SALE SECURITIES
|
343 | (534 | ) | (7 | ) | (490 | ) | |||||||||
|
TOTAL OTHER COMPREHENSIVE LOSS (INCOME)
|
352 | (544 | ) | (7 | ) | (513 | ) | |||||||||
|
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD
|
$ | 3,885 | $ | 1,695 | $ | 1,630 | $ | 602 | ||||||||
|
LOSS PER COMMON SHARE
:
|
||||||||||||||||
|
BASIC AND DILUTED LOSS PER COMMON SHARE
|
$ | 0.34 | $ | 0.26 | $ | 0.15 | $ | 0.12 | ||||||||
|
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON STOCK
|
10,482,190 | 8,531,150 | 10,826,146 | 9,127,799 | ||||||||||||
The accompanying notes are an integral part of the condensed consolidated financial statements.
F-3
ORAMED PHARM
AC
EUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(UNAUDITED)
U.S. Dollars in thousands (except for share data)
|
Accumulated
|
||||||||||||||||||||||||
|
Additional
|
other
|
Total
|
||||||||||||||||||||||
|
Common Stock
|
paid-in
|
comprehensive
|
Accumulated
|
stockholders'
|
||||||||||||||||||||
|
Shares
|
$ |
capital
|
income
|
loss
|
equity
|
|||||||||||||||||||
|
In thousands
|
||||||||||||||||||||||||
|
BALANCE AS OF AUGUST 31, 2014
|
10,103 | $ | 121 | $ | 48,040 | $ | 452 | $ | (27,820 | ) | $ | 20,79 3 | ||||||||||||
|
SHARES ISSUED FOR CASH, NET
|
696 | 8 | 4,825 | - | - | 4,833 | ||||||||||||||||||
|
SHARES ISSUED FOR SERVICES
|
4 | * | 26 | - | - | 26 | ||||||||||||||||||
|
EXERCISE OF OPTIONS
|
1 | * | 8 | - | - | 8 | ||||||||||||||||||
|
STOCK BASED COMPENSATION
|
16 | * | 564 | - | - | 564 | ||||||||||||||||||
|
NET LOSS
|
- | - | - | - | (3,533 | ) | (3,533 | ) | ||||||||||||||||
|
OTHER COMPREHENSIVE LOSS
|
- | - | - | (352 | ) | - | (352 | ) | ||||||||||||||||
|
BALANCE AS OF FEBRUARY 28, 2015
|
10,820 | $ | 129 | $ | 53,463 | $ | 100 | $ | (31,353 | ) | $ | 22,339 | ||||||||||||
|
*
|
Represents an amount of less than $1.
|
The accompanying notes are an integral part of the condensed consolidated financial statements.
F-4
ORAMED PHARMA
CE
UTICALS INC.
CONDENSED
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(UNAUDITED)
U.S. dollars in thousands
|
Six months ended
|
||||||||
|
February 28,
|
February 28,
|
|||||||
|
2015
|
2014
|
|||||||
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
||||||||
|
Net loss
|
$ | (3,533 | ) | $ | (2,239 | ) | ||
|
Adjustments required to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Depreciation and amortization
|
3 | 3 | ||||||
|
Exchange differences and interest on deposits
|
(36 | ) | (33 | ) | ||||
|
Stock based compensation
|
564 | 333 | ||||||
|
Common stock issued for services
|
26 | 64 | ||||||
|
Gain on sale of investment
|
- | (44 | ) | |||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Prepaid expenses, other current assets and related parties
|
341 | (167 | ) | |||||
|
Accounts payable, accrued expenses and related parties
|
(368 | ) | (148 | ) | ||||
|
Liability for employee rights upon retirement
|
- | 1 | ||||||
|
Total net cash used in operating activities
|
(3,003 | ) | (2,230 | ) | ||||
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
||||||||
|
Purchase of property and equipment
|
(2 | ) | (9 | ) | ||||
|
Purchase of short term deposits
|
(1,573 | ) | (18,600 | ) | ||||
|
Purchase of long term deposits
|
(4,652 | ) | - | |||||
|
Proceeds from sale of short term deposits
|
3,750 | 5,236 | ||||||
|
Proceeds from sale of marketable securities
|
- | 80 | ||||||
|
Funds in respect of employee rights upon retirement
|
- | (1 | ) | |||||
|
Total net cash used in investing activities
|
(2,477 | ) | (13,294 | ) | ||||
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
|
Proceeds from issuance of common stock - net of issuance expenses*
|
4,833 | 14,887 | ||||||
|
Proceeds from exercise of warrants and options
|
8 | 1,490 | ||||||
|
Proceeds from shares to be issued for exercise of warrants
|
- | 118 | ||||||
|
Net cash derived from financing activities
|
4,841 | 16,495 | ||||||
|
EFFECT OF EXCHANGE RATE CHANGES ON CASH
|
(21 | ) | 10 | |||||
|
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
|
(660 | ) | 981 | |||||
|
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD
|
1,762 | 2,272 | ||||||
|
CASH AND CASH EQUIVALENTS AT END OF PERIOD
|
$ | 1,102 | $ | 3,253 | ||||
|
*
|
See note 5.
|
The accompanying notes are an integral part of the condensed consolidated financial statements.
F-5
|
|
O
RA
MED PHARMACEUTICALS Inc.
|
|
|
(A development stage company)
|
|
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
(UNAUDITED)
U.S. Dollars in thousands (except share and per share data)
|
a.
|
General:
|
|
1)
|
Incorporation and operations
|
Oramed Pharmaceuticals Inc. (the “Company”) was incorporated on April 12, 2002, under the laws of the State of Nevada. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd (“Hadasit”) to acquire the provisional patent related to an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes.
On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.
On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development. Unless the context indicates otherwise, the term “Group” refers to Oramed Pharmaceuticals Inc. and the Subsidiary.
Following the adoption of Accounting Standards Update (“ASU”) 2014-10, Development Stage Entities (Topic 915), the Company removed the inception to date information and all reference to development.
|
|
2)
|
Development and liquidity risks
|
The Group is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated any revenues from its operations. Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable.
Successful completion of the Company’s development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the U.S. Food and Drug Administration (“FDA”) prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company’s ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.
F-6
|
|
ORAMED PHARMACEUTICALS Inc.
|
|
|
(A development stage company)
|
|
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
(UNAUDITED)
U.S. Dollars in thousands (except share and per share data)
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
(continued):
Based on its current cash resources and commitments, and cash received in private and public offerings in the six month period ended February 28, 2015 and in the year ended August 31, 2014, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months and beyond the date that the financial statements are issued, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.
|
b.
|
Newly issued and recently adopted Accounting Pronouncements
|
In August 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). This new standard requires management to assess the entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 will be effective prospectively for annual reporting periods ending after the first annual period ending after December 15, 2016 and interim periods therein. Early application of the standard is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued. The Company has elected to early adopt the provisions of ASU 2014-15 in fiscal year 2014. The adoption of ASU 2014-15 did not have any material effect on the consolidated financial statement presentation.
F-7
|
|
ORAMED PHARMACEUTICALS Inc.
|
|
|
(A development stage company)
|
|
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
(UNAUDITED)
U.S. Dollars in thousands (except share and per share data)
|
c.
|
Condensed Consolidated Financial Statements Preparation
|
The condensed consolidated financial statements included herein have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") and on the same basis as the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2014 (the “2014 Form 10-K”). These condensed consolidated financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair statement of the results of the periods presented. Certain information and disclosures normally included in annual consolidated financial statements have been omitted in this interim period report pursuant to the rules and regulations of the Securities and Exchange Commission. Because the condensed consolidated interim financial statements do not include all of the information and disclosures required by U.S. GAAP for annual financial statements, they should be read in conjunction with the audited consolidated financial statements and notes included in the 2014 Form 10-K. The results for interim periods are not necessarily indicative of a full fiscal year’s results.
|
|
a.
|
On
September 11, 2011, the Subsidiary entered into an agreement with Hadasit, the Company's Medical and Chief Technology Officer (the “CTO”) and Dr. Daniel Schurr
Subsidiary
(the “Hadasit Agreement”) to retain consulting and clinical trial services. According to the Hadasit Agreement, Hadasit will be entitled to a consideration of $200 to be paid by the Subsidiary in accordance with the actual progress of the studies, $95 of which were recognized through February 28, 2015. See also note 1a(1).
|
|
|
b.
|
On February 15, 2011, the Subsidiary entered into a consulting agreement with a third party (the “Consultant”) for a period of five years, pursuant to which the Consultant will provide consultation on scientific and clinical matters. The Consultant is entitled to a fixed monthly fee of $8, royalties of 8% of the net royalties actually received by the Subsidiary in respect of the patent that was sold to Entera Bio Ltd. (“Entera”) on March 31, 2011 and an option to purchase up to 20,834 shares of the Company at an exercise price of $6.00 per share. The option vests in five annual installments commencing February 16, 2012 and expires on February 16, 2021. The fair value of the option as of February 28, 2015 was $105, using the following assumptions: dividend yield of 0%; expected term of 5.97 years; expected volatility of 79.74%; and risk-free interest rate of 1.86%. The fair value of the unvested options is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.
|
F-8
|
|
ORAMED PHARMACEUTICALS Inc.
|
|
|
(A development stage company)
|
|
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
(UNAUDITED)
U.S. Dollars in thousands (except share and per share data)
NOTE 2 - COMMITMENTS
(continued):
|
|
c.
|
On April 28, 2013, the Subsidiary entered into a new lease agreement for its office facilities in Israel, which replaced the lease agreement from 2012. The new lease agreement is for a period of 36 months commencing November 4, 2013. The annual lease payment is NIS 89,000 from 2014 through 2016, and will be linked to the increase in the Israeli consumer price index (“CPI”) (as of February 28, 2015, the future annual lease payments under the new agreement will be $22, based on the exchange rate as of February 28, 2015).
|
As security for its obligation under this lease agreement the Company provided a bank guarantee in an amount equal to three monthly lease payments.
|
|
d.
|
On May 13, 2014, the Company entered into a consulting agreement with a third party advisor for a period of twelve months, pursuant to which the advisor will provide investor relations services and will be entitled to receive a monthly cash fee and 15,000 shares of the Company’s common stock that will be issued in four equal installments, on
or about
each of August 1, 2014, November 1, 2014, February 1, 2015 and May 1, 2015. As of February 28, 2015, the Company issued to such advisor 7,500 shares. The aggregate fair value of the shares at the dates of the grant was $64.
|
|
|
e.
|
On February 6, 2014, the Subsidiary entered into a second agreement with a clinical research organization (“CRO”), for its Phase IIa clinical trial for an oral insulin capsule for type 1 diabetes patients, which was completed in October 2014. As consideration for its services, the Subsidiary paid the CRO a total amount of approximately $280 during the term of the engagement and based on achievement of certain milestones, all of which were recognized through February 28, 2015.
|
On July 22, 2014, the Subsidiary entered into a third agreement with the same CRO, for its Phase IIb clinical trial for an oral insulin capsule for type 2 diabetes patients, which is expected to begin in the second quarter of calendar year 2015. As consideration for its services, the Subsidiary will pay the CRO a total amount of approximately
$3,290 during the term of the engagement and based on achievement of certain milestones, $761 of which were recognized through February 28, 2015.
|
|
f.
|
On March 3, 2014, the Subsidiary entered into an additional agreement with a vendor, for the process development and production of one of its oral capsule ingredients in the amount of $311, $40 of which were recognized through February 28, 2015, and bonus payments of up to $600 that will be paid upon achieving certain milestones, as described in the agreement and which were not recognized through February 28, 2015.
|
On May 15, 2014, the Subsidiary entered into an additional agreement with the same vendor, for the process development and production of the same capsule ingredients in the amount of $217, all of which was recognized through February 28, 2015.
On December 12, 2014, the Subsidiary entered into an additional agreement with the same vendor, for the process development and production of the same capsule ingredients in the amount of $550, $202 of which was recognized through February 28, 2015.
F-9
|
|
ORAMED PHARMACEUTICALS Inc.
|
|
|
(A development stage company)
|
|
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
(UNAUDITED)
U.S. Dollars in thousands (except share and per share data)
|
|
g.
|
On May 26, 2014, the Subsidiary entered into a supply agreement with another vendor, according to which the vendor will manufacture capsules for total consideration of $214, $174 of which was recognized through February 28, 2015.
|
|
|
h.
|
On February 2, 2015, the Subsidiary entered into an agreement with a different CRO, for a glucose clamp clinical study for its oral insulin capsule. As consideration for its services, the Subsidiary will pay the CRO a total amount of approximately
$276 during the term of the engagement and based on achievement of certain milestones, none of which was recognized through February 28, 2015.
|
|
i.
|
On January 20, 2015, the Subsidiary entered into a purchase order for the manufacturing of insulin capsules for total consideration of Swiss Franc (“CHF”) 211 (approximately $241) of which CHF 104 (approximately $118) was recognized through February 28, 2015.
|
|
|
j.
|
Grants from Bio-Jerusalem
|
The Subsidiary is committed to pay royalties to the Bio-Jerusalem fund on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received by the Company (Israeli CPI linked) at the total amount of $65. As of February 28, 2015, the Subsidiary had not yet realized any revenues and did not incur any royalty liability.
During the six month period ended February 28, 2015, the Company received no grants from the Bio-Jerusalem fund.
|
|
k.
|
Grants from the Office of the Chief Scientist of the Ministry of Economy (formerly the Ministry of Industry, Trade and Labor) of Israel (“OCS”).
|
Under the terms of the Company’s funding from the OCS, royalties of 3%-3.5% are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Company (dollar linked) with the addition of annual interest at a rate based on LIBOR.
At the time the grants were received, successful development of the related projects was not assured. In case of failure of a project that was partly financed as above, the Company is not obligated to pay any such royalties.
As of February 28, 2015, the Subsidiary had not yet realized any revenues from said projects and did not incur any royalty liability. The total amount that was actually received through February 28, 2015 was $2,160.
|
j.
|
For the six and three month periods ended February 28, 2015, the research and development expenses are presented net of OCS and Bio-Jerusalem fund grants, in the total amount of $17 and $1, respectively.
|
F-10
|
|
ORAMED PHARMACEUTICALS Inc.
|
|
|
(A development stage company)
|
|
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
(UNAUDITED)
U.S. Dollars in thousands (except share and per share data)
Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:
|
Level 1:
|
Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
|
|
Level 2:
|
Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
|
|
Level 3:
|
Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
|
As of February 28, 2015, the assets or liabilities measured at fair value were comprised of available for sale securities (Level 1). See also note 4.
As of February 28, 2015, the carrying amount of cash and cash equivalents, short term deposits, other current assets, accounts payables and accrued expenses approximates their fair values due to the short-term maturities of these instruments
.
The fair value of long-term deposits also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. The long-term bank deposits bear an annual interest rate of 0.93%-1.00% and will mature during the third quarter of fiscal year 2016. The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.
Available-for-sale securities are reported at fair value, with unrealized gains and losses recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities.
The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and the Company’s ability and intent to hold the investment. Realized gains and losses on sales of the securities are included in the consolidated statement of operations as financial income or expenses.
As of February 28, 2015, marketable securities consisted wholly of equity securities of D.N.A Biomedical Solutions Ltd ("D.N.A"). D.N.A’s ordinary shares are traded on the Tel Aviv Stock Exchange and have a quoted price. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.
F-11
|
|
ORAMED PHARMACEUTICALS Inc.
|
|
|
(A development stage company)
|
|
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
(UNAUDITED)
U.S. Dollars in thousands (except share and per share data)
During the six month period ended February 28, 2014, the Subsidiary sold in aggregate 1,625,989 of the D.N.A ordinary shares for total consideration of $80. During the six month period ended February 28, 2015, the Group did not sell any of the D.N.A ordinary shares.
As of February 28, 2015, the Group owns approximately 9.8% of D.N.A’s outstanding ordinary shares.
The cost of the securities as of February 28, 2015 and August 31, 2014 is $595.
The cost of the securities sold and the amount reclassified out of accumulated other comprehensive income into financial income (amounting to $0 and $44 during the six month periods ended February 28, 2015 and 2014, respectively, and to $0 and $26 during the three month periods ended February 28, 2015 and 2014, respectively) were determined by specific identification.
On November 3, 2014, the Company entered into a Stock Purchase Agreement with Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd. (the “Investor”), pursuant to which the Company issued to the Investor an aggregate of 696,378 shares of common stock, at a price of $7.18 per share, which was equal to the closing price of the Company’s common stock on the Nasdaq Capital Market on October 31, 2014, for aggregate gross proceeds of approximately $5,000. The net proceeds to the Company from the offering were approximately $4,833, after deducting a finder's fee of $150 and other offering expenses of the Company. The offering closed on November 28, 2014.
See also note 8 with respect to an at market issuance sales agreement.
|
a.
|
On November 13, 2014, the Company granted a total of 19,576 restricted stock units (“RSUs”) representing a right to receive shares of the Company’s common stock to the Company’s Chief Executive Officer and director (the “CEO”), and the CTO, both related parties. The RSUs vested in two equal installments, each of 9,788 shares, on November 30 and December 31, 2014. The total fair value of these RSUs on the date of grant was $135, using the quoted closing market share price of $6.90 on the Nasdaq Capital Market on the date of grant. The shares of common stock underlying the RSUs will be issued upon request of the grantee.
As of February 28, 2015, a total of 19,576 RSUs were vested and outstanding.
|
|
b.
|
On November 13, 2014, the Company granted a total of 10,872 RSUs representing a right to receive shares of the Company’s common stock to four members of the Company's Board of Directors. The RSUs vested on January 1, 2015. The total fair value of these RSUs on the date of grant was $75, using the quoted closing market share price of $6.90 on the Nasdaq Capital Market on the date of grant.
|
F-12
|
|
ORAMED PHARMACEUTICALS Inc.
|
|
|
(A development stage company)
|
|
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
(UNAUDITED)
U.S. Dollars in thousands (except share and per share data)
|
c.
|
On February 23, 2015, the Company granted a total of 159,696 RSUs representing a right to receive shares of the Company’s common stock to the Company’s CEO and the CTO, both related parties. The RSUs vest in 23 installments consisting of one installment of 13,308 shares on February 28, 2015 and 22 equal monthly installments of 6,654 shares each, commencing March 31, 2015. The total fair value of these RSUs on the date of grant was $728, using the quoted closing market share price of $4.56 on the Nasdaq Capital Market on the date of grant. The shares of common stock underlying the RSUs will be issued upon request of the grantee. As of February 28, 2015, a total of 13,308 RSUs were vested and outstanding.
|
|
d.
|
On February 23, 2015, the Company granted a total of 88,712 RSUs representing a right to receive shares of the Company’s common stock to four members of the Company's Board of Directors (22,178 RSUs to each director). The RSUs vest in two equal installments, each of 44,356 shares, on December 31, 2015 and December 31, 2016. The total fair value of these RSUs on the date of grant was $405, using the quoted closing market share price of $4.56 on the Nasdaq Capital Market on the date of grant.
|
|
e.
|
On February 23, 2015, the Company granted a total of 46,560 RSUs to an employee of the Subsidiary. The RSUs vest in 23 installments, consisting of one installment of 3,880 shares on February 28, 2015 and 22 equal monthly installments of 1,940 shares each, commencing March 31, 2015. The total fair value of these RSUs on the date of grant was $212, using the quoted closing market share price of $4.56 on the Nasdaq Capital Market on the date of grant.
|
|
f.
|
On February 23, 2015, the Company granted a total of 16,656 RSUs to employees of the Subsidiary. The RSUs vest in 23 installments, consisting of one installment of 1,388 shares on February 28, 2015 and 22 equal monthly installments of 694 shares each, commencing March 31, 2015. The total fair value of these RSUs on the date of grant was $76, using the quoted closing market share price of $4.56 on the Nasdaq Capital Market on the date of grant.
|
On July 1, 2008, the Subsidiary entered into two consulting agreements with KNRY Ltd. (“KNRY”), an Israeli company owned by the CEO, whereby the CEO and the CTO, through KNRY, provide services to the Group (the “Consulting Agreements”). The Consulting Agreements are both terminable by either party upon 60 days prior written notice. The Consulting Agreements provide that KNRY (i) will be paid a gross amount of NIS 50,400 per month for each of the CEO and CTO ($14) and (ii) will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements.
F-13
|
|
ORAMED PHARMACEUTICALS Inc.
|
|
|
(A development stage company)
|
|
|
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
(UNAUDITED)
U.S. Dollars in thousands (except share and per share data)
On July 17, 2013, the Subsidiary entered into amendments to the Consulting Agreements with KNRY, according to which, the CEO's and CTO's annual payment was set at $250 and $200, respectively, calculated at an exchange rate of NIS 3.6 per U.S. dollar, and in addition to such payment they were granted the use of a company car and certain cash bonus payments, effective July 1, 2013.
On November 13, 2014, the Subsidiary entered into an amendment to the Consulting Agreements (the “Amendment Agreement”), according to which, the CEO and the CTO made some representations with regards to their relationship with KNRY and agreed to indemnify the Subsidiary in certain circumstances as defined in the amendment, among other revisions.
On April 2, 2015, the Company entered into an at market issuance sales agreement (the “Sales Agreement”) with MLV & Co. LLC (“MLV”) pursuant to which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $25 million from time to time, at its option, through MLV as its sales agent, subject to certain terms and conditions. Any shares sold will be sold pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-193557), including a prospectus dated April 10, 2014, as supplemented by a prospectus supplement dated April 2, 2015. The Company will pay MLV a commission of 3.0% of the gross proceeds of the sale of any shares sold through MLV. To date, no shares have been sold under the Sales Agreement.
F-14
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and the related notes included elsewhere herein and in our consolidated financial statements, accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in our Annual Report (as defined below).
Forward-Looking Statements
This Quarterly Report on Form 10-Q (including the section regarding Management’s Discussion and Analysis of Financial Condition and Results of Operations) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, regarding our business, clinical trials, financial condition, expenditures, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “planned expenditures,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this Quarterly Report on Form 10-Q. Additionally, statements concerning future matters are forward-looking statements.
Although forward-looking statements in this Quarterly
Report on Form 10-Q reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended August 31, 2014, or our Annual Report, as filed with the Securities and Exchange Commission, or the SEC, on November 14, 2014, as well as those discussed elsewhere in our Annual Report and in this Quarterly
Report on Form 10-Q. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly
Report on Form 10-Q. Except as required by law, we undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report on Form 10-Q. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this Quarterly
Report on Form 10-Q which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.
Overview of Operations
We are a pharmaceutical company currently engaged in the research and development of innovative pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides.
2
Recent business developments
Product Candidates
In September 2013, we submitted a pre-Investigational New Drug, or pre-IND, package to the U.S. Food and Drug Administration, or FDA, for ORMD-0901, our oral exenatide capsule, for a Phase 2 clinical trial on healthy volunteers and type 2 diabetic patients. We began pre-clinical studies in November 2014 and expect to begin non-U.S. based Phase Ib trials and IND-enabling studies in the second quarter of calendar year 2015. We then intend to then file an IND and move immediately and directly into a large Phase II multi-center trial in the U.S.
We originally filed an IND with the FDA in December 2012 for clearance to begin a Phase II clinical trial of ORMD-0801, in order to evaluate the safety, tolerability and efficacy of our oral insulin capsule on type 2 diabetic volunteers. Because the identical formulation of ORMD-0801 had not yet been studied in humans at bedtime, in February 2013 the FDA noted concerns about mitigating potential risks of severe hypoglycemia and requested that we perform a sub-study in a controlled in-patient setting for a one-week period prior to beginning the larger multi-centered Phase II trial. As a result, we withdrew the original IND and, in April 2013, we submitted a new IND for the Phase IIa sub-study. Following the FDA’s clearance to proceed in May 2013, we began the Phase IIa sub-study in July 2013. As we announced in January 2014, the Phase IIa sub-study met all primary and secondary endpoints. Specifically, the Phase IIa study evaluated the pharmacodynamic effects of ORMD-0801 on mean nighttime glucose (determined using a continuous glucose monitor). The results showed that ORMD-0801 exhibited a sound safety profile, led to reduced mean daytime and nighttime glucose readings and lowered fasting blood glucose concentrations, when compared to placebo. In addition, no serious adverse events occurred during this study, and the only adverse events that occurred were not drug related. In light of these results, we believe that we should move forward with the Phase IIb clinical trial on approximately 180 type 2 diabetic patients and it will be conducted in approximately 30 sites in the United States, which we are preparing to initiate in the second quarter of calendar year 2015. This double-blind, randomized, 28-day study clinical trial will be designed to assess the safety and efficacy of ORMD-0801 and will investigate ORMD-0801 over a longer treatment period and which will have statistical power to give us greater insight into the drug’s efficacy. We anticipate the last patient will complete this trial before the end of 2015.
We are also conducting an additional study of our oral insulin capsule on type 2 diabetic volunteers that will be performed at The University of Texas Health Science Center at San Antonio and University Health System’s Texas Diabetes Institute. The glucose clamp is a method for quantifying insulin absorption in order to measure a patient’s insulin sensitivity and how well a patient metabolizes glucose. As announced, the first patient has been enrolled and we anticipate
completing
the study in the fourth quarter of calendar year 2015.
In February 2014, we submitted a protocol to the FDA to initiate a Phase IIa trial of our oral insulin capsule for type 1 diabetes volunteers. The protocol was submitted under our existing IND to include both type 1 and type 2 diabetes indications. The double-blind, randomized, placebo controlled, seven-day study design was carried out at an inpatient setting on 25 type 1 diabetic patients. We began this study in March 2014. As we announced in October 2014, the results showed that ORMD-0801 oral insulin given before meals appeared to be safe and well-tolerated for the dosing regimen in this study. Although the study was not powered to show statistical significance, there were internally consistent trends observed. Consistent with the timing of administration, the data showed a decrease in rapid acting insulin, a decrease in post-prandial glucose, a decrease in daytime glucose by continual glucose monitoring and an increase in post-prandial hypoglycemia in the active group.
The table below gives an overview of our product pipeline:
|
Phase I
|
Phase II
|
Phase III
|
Timeline
|
|||
|
ORMD-0801
oral insulin
|
Type 2 diabetes
|
|
Q1 ’14: Phase IIa completed
Q2 ’15: Phase IIb multi-center study projected initiation
|
|||
|
Type 1 diabetes
|
|
Q3 ’14: Phase IIa completed
|
||||
|
ORMD-0901
oral GLP-1
|
Type 2 diabetes
|
|
Q3 ’14: Preclinical/IND studies initiated
Q2 ’15: Phase Ib ex-US study projected initiation.
Q1
’16: Phase II multi-center study projected initiation
|
|||
3
Results of Operations
Comparison of six and three month periods ended February 28, 2015 and 2014
The following table summarizes certain statements of operations data for the Company for the six and three month periods ended February 28, 2015 and 2014 (in thousands of dollars except share and per share data):
|
Six months ended
|
Three months ended
|
||||||||||||||
|
February 28,
|
February 28,
|
||||||||||||||
|
2015
|
2014
|
2015
|
2014
|
||||||||||||
|
Research and development expenses, net
|
$
|
2,438
|
$
|
1,424
|
$
|
1,136
|
$
|
674
|
|||||||
|
General and administrative expenses
|
1,138
|
930
|
538
|
512
|
|||||||||||
|
Financial income, net
|
(43
|
)
|
(115
|
)
|
(37
|
)
|
(71
|
)
|
|||||||
|
Net loss for the period
|
$
|
3,533
|
$
|
2,239
|
$
|
1,637
|
$
|
1,115
|
|||||||
|
Loss per common share – basic and diluted
|
$
|
(0.34
|
)
|
$
|
(0.26
|
)
|
$
|
(0.15
|
)
|
$
|
(0.12
|
)
|
|||
|
Weighted average common shares outstanding
|
10,482,190
|
8,531,150
|
10,826,146
|
9,127,799
|
|||||||||||
Research and development expenses
Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, costs of materials, supplies, the cost of services provided by outside contractors, including services related to our clinical trials, clinical trial expenses, the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred.
4
Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. We outsource a substantial portion of our clinical trial activities, utilizing external entities such as contract research organizations, or CROs, independent clinical investigators, and other third-party service providers to assist us with the execution of our clinical studies.
Clinical activities which relate principally to clinical sites and other administrative functions to manage our clinical trials are performed primarily by CROs. CROs typically perform most of the start-up activities for our trials, including document preparation, site identification, screening and preparation, pre-study visits, training, and program management.
Clinical trial and pre-clinical trial expenses include regulatory and scientific consultants’ compensation and fees, research expenses, purchase of materials, cost of manufacturing of the oral insulin capsules, payments for patient recruitment and treatment, as well
as salaries and related expenses of research and development staff.
Research and development expenses, for the six months ended February 28, 2015 increased by 71% to $2,438,000, from $1,424,000 for the six months ended February 28, 2014. The increase is mainly attributable to preparing for the initiation of our Phase IIb clinical trial. Stock-based compensation costs for the six months ended February 28, 2015 totaled $293,000, as compared to $295,000 during the six months ended February 28, 2014.
Research and development
expenses
, for the
three months ended February 28, 2015
increased by 69% to
$1,136,000, from $674,000 for the three months ended February 28, 2014. The increase is mainly attributable to preparing for the initiation of our Phase IIb clinical trial. Stock-based compensation costs for the three months ended February 28, 2015 totaled $129,000, as compared to $117,000 during the three months ended February 28, 2014.
Government grants
In March 2014, our Israeli subsidiary, Oramed Ltd., was granted a fifth grant amounting to a total amount of NIS 1,206,990 (approximately $345,000) from the Office of the Chief Scientist of the Ministry of Economy of Israel, or OCS, which was designated for research and development expenses for the period of November 2013 to October 2014. In September 2014, the OCS extended the period of this fifth year until December 2014. We used the funds to support further research and development and clinical studies of our oral insulin capsule and oral GLP-1 analog.
In the six and three month periods ended February 28, 2015, we recognized research and development grants in an amount of $17,000, and $1,000, respectively, and in the six months ended February 28, 2014, we recognized research and development grants in an amount of $139,000. In the three months ended February 28, 2014, we recognized no grants from the OCS. As of February 28, 2015, we had no contingent liabilities to the OCS.
General and administrative expenses
General and administrative expenses include the salaries and related expenses of our management, consulting costs, legal and professional fees, traveling, business development costs, insurance expenses and other general costs.
General and administrative expenses for the six months ended February 28, 2015 increased by 22% to $1,138,000 from $930,000 for the six months ended February 28, 2014. The increase in costs incurred related to general and administrative activities during the six months ended February 28, 2015 is mainly due to the increase in stock-based compensation expenses, which increased from $38,000 during the six months ended February 28, 2014 to $272,000 in the six months ended February 28, 2015, which is attributed to awards granted to directors and officers during the six months ended February 28, 2015.
5
General and administrative expenses for the three months ended February 28, 2015 increased by 5% to $538,000 from $512,000 for the three months ended February 28, 2014. The increase in costs incurred related to general and administrative activities during the three months ended February 28, 2015 is mainly due to the increase in stock-based compensation expenses, which increased from $12,000 during the three months ended February 28, 2014 to $136,000 in the three months ended February 28, 2015, which is attributed to awards granted to directors and officers during the three months ended February 28, 2015, which was offset by a decrease in
salaries and related expenses resulting from cash bonuses to employees
paid during the three months ended February 28, 2014.
Financial income, net
Net financial income decreased by 63% from net income of $115,000 for the six months ended February 28, 2014 to net income of $43,000 for the six months ended February 28, 2015. The decrease is mainly due to a decrease in income from exchange rate differences and to a decrease in capital gain on marketable securities, which decreased from $44,000 during the six months ended February 28, 2014 to zero in the six months ended February 28, 2015.
During the three months ended February 28, 2015, net financial income totaled $37,000, compared to $71,000 for the three months ended February 28, 2014. The decrease of 48% in net financial income during the three months ended February 28, 2015, as compared to the three months ended February 28, 2014, is attributable to the same reasons described above.
Other comprehensive income
Subsequent decrease in the fair value of available for sale securities previously written down as impaired for the six months ended February 28, 2015 of $9,000 resulted from the decrease in fair value of the ordinary shares of D.N.A Biomedical Solutions Ltd, or D.N.A, that we hold, and
subsequent increase in the fair value of available for sale securities previously written down as impaired for the six months ended February 28, 2014 of $54
,000
resulted from the increase in fair value of the
shares o
f D.N.A that we hold
. Unrealized losses on available for sale securities for the six months ended February 28, 2015 of $343,000, resulted from the decrease in fair value of our D.N.A ordinary shares.
Unrealized gains on available for sale securities for the six months ended February 28, 2014 of $534,
000
, resulted from the increase in fair value of our D.N.A ordinary shares. Reclassification adjustments for gains included in net loss for the six months ended February 28, 2014 of $44,
000
, resulted from the sale of 1,625,989 of our D.N.A ordinary shares in October and November 2013 and January 2014.
Subsequent increase in the fair value of available for sale securities previously written down as impaired for the three months ended February 28, 2014 of $49,000 resulted from the increase in fair value of the D.N.A
ordinary
shares, while there was no change in the
fair value of available for sale securities previously written down as impaired for the three months ended February 28, 2015
. Unrealized gains on available for sale securities for the three months ended February 28, 2014 and 2015 of $490,000 and $7,000, respectively, resulted from the increase in fair value of our D.N.A ordinary shares.
Liquidity and capital resources
From inception through February 28, 2015, we have incurred losses in an aggregate amount of $31,353,000. During that period we have financed our operations through several private placements of our common stock, as well as public offerings of our common stock, raising a total of $40,580,000, net of transaction costs. During that period we also received cash consideration of $1,870,000 from the exercise of warrants and options. We will seek to obtain additional financing through similar sources in the future as needed. As of February 28, 2015, we had $1,102,000 of available cash, $16,351,000 of short term bank deposits, $4,660,000 of long term bank deposits and $695,000 of marketable securities. We anticipate that we will require approximately $10.2 million to finance our activities during the 12 months following February 28, 2015.
6
Management continues to evaluate various financing alternatives for funding future research and development activities and general and administrative expenses through fundraising in the public or private equity markets. Although there is no assurance that we will be successful with those initiatives, management believes that it will be able to secure the necessary financing as a result of ongoing financing discussions with third party investors, including the investor in connection with the private placement entered into in November 2014, and existing stockholders, future public offerings, and additional funding from the OCS. Based on our current cash resources and commitments, including cash received in a private placement in the period ended February 28, 2015, we believe we will be able to maintain our current planned development activities and the corresponding level of expenditures for at least the next 12 months and beyond.
As of February 28, 2015, our total current assets were $18,295,000 and our total current liabilities were $605,000. On February 28, 2015, we had a working capital surplus of $17,690,000 and an accumulated loss of $31,353,000. As of August 31, 2014, our total current assets were $21,778,000 and our total current liabilities were $973,000. On August 31, 2014, we had a working capital surplus of $20,805,000 and an accumulated loss of $27,820,000. The decrease in working capital from August 31, 2014 to February 28, 2015 was primarily due to the investment of a portion of the proceeds from our private placement completed in November 2014 in long term bank deposits.
During the six month period ended February 28, 2015, cash and cash equivalents decreased to $1,102,000 from the $1,762,000 reported as of August 31, 2014, which is due to the reasons described below.
Operating activities used cash of $3,003,000 in the six month period ended February 28, 2015, as compared to $2,231,000 used in the six months ended February 28, 2014. Cash used for operating activities in the six months ended February 28, 2015 and 2014 primarily consisted of net loss resulting from research and development and general and administrative expenses, partially offset by stock-based compensation amounts.
During the six month period ended February 28, 2015, we received $93,000 in OCS grants towards our research and development expenses, while we recognized the amount of $17,000 during such period and $139,000 was recognized in the six month period ended February 28, 2014. During the six month period ended February 28, 2014, we received $125,000 in OCS grants. The amounts that were received but not recognized during the six month period ended February 28, 2015 were recognized during fiscal year 2014. The OCS has supported our activity in the past five years.
Investing activities used cash of $2,477,000 in the six month period ended February 28, 2015, as compared to $13,294,000 used in the six month period ended February 28, 2014. Cash used in investing activities in the six months ended February 28, 2015 consisted primarily of the investment in long term bank deposits, while cash used in investing activities in the six months ended February 28, 2014 consisted primarily of the acquisition of short-term bank deposits.
Financing activities provided cash of $4,841,000 in the six month period ended February 28, 2015, as compared to $16,495,000 in the six month period ended February 28, 2014. Financing activities in the six month periods ended February 28, 2015 and 2014 consisted of proceeds from our issuance of common stock and proceeds from exercise of warrants and options in each period.
At the Market Issuance Sales Agreement
On April 2, 2015, we entered into an at the market issuance sales agreement, or the Sales Agreement, with MLV & Co. LLC, or MLV, pursuant to which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $25 million from time to time, at its option, through MLV as its sales agent, subject to certain terms and conditions. Any shares sold will be sold pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-193557), including a prospectus dated April 10, 2014, as supplemented by a prospectus supplement dated April 2, 2015. The Company will pay MLV a commission of 3.0% of the gross proceeds of the sale of any shares sold through MLV. To date, no shares have been sold under the Sales Agreement.
Off-balance sheet arrangements
As of
February 28, 2015
, we had no off balance sheet arrangements that have had or that we expect would be reasonably likely to have a future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
7
Planned Expenditures
The estimated expenses referenced herein are in accordance with our business plan. Since our technology is still in the development stage, it can be expected that there will be changes in some budgetary items. Our planned expenditures for the twelve months beginning March 1, 2015 are as follows (in thousands):
|
Category
|
Amount
|
|||
|
Research and development, net of OCS funds
|
$
|
7,933
|
||
|
General and administrative expenses
|
2,268
|
|||
|
Total
|
$
|
10,201
|
||
In December 2012 and April 2013, we filed IND applications with the FDA for our orally ingested insulin and we are conducting, or planning to conduct, further clinical studies with our oral exenatide capsule, and others. Our ability to complete these expected activities is dependent on several major factors including the ability to attract sufficient financing on terms acceptable to us
.
There has been no significant change in our exposure to market risk during the three months ended February 28, 2015. For a discussion of our exposure to market risk, refer to Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” contained in our Annual Report on Form 10-K for the year ended August 31, 2014.
Disclosure Controls and Procedures
Our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of February 28, 2015. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective
.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the quarter ended
February 28, 2015
that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
8
See Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations – At the Market Issuance S
ales
Agreement.”
|
Number
|
Exhibit
|
|
| 5.1* | Opinion of Zysman, Aharoni, Gayer and Sullivan & Worcester LLP. | |
| 10.1* | At the Market Issuance Sales Agreement, dated April 2, 2015, by and between Oramed Pharmaceuticals Inc. and MLV & CO. LLC. | |
| 23.1* | Consent of Zysman, Aharoni, Gayer and Sullivan & Worcester LLP (included in Exhibit 5.1). | |
|
31.1*
|
Certification Statement of Principal Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.
|
|
|
31.2*
|
Certification Statement of Principal Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.
|
|
|
32.1**
|
Certification Statement of Principal Executive Officer pursuant to 18 U.S.C. Section 1350.
|
|
|
32.2**
|
Certification Statement of Principal Financial Officer pursuant to 18 U.S.C. Section 1350.
|
|
|
101.1*
|
The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended
February 28, 2015
, formatted in XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Comprehensive Loss, (iii) Condensed Consolidated Statements of Changes in Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) the Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and in detail.
|
___________________
|
*
|
Filed herewith
|
|
**
|
Furnished herewith
|
9
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
ORAMED PHARMACEUTICALS INC.
|
|||
|
Date: April 2, 2015
|
By:
|
/s/ Nadav Kidron
|
|
|
Nadav Kidron
|
|||
|
President and Chief Executive Officer
|
|||
|
Date: April 2, 2015
|
By:
|
/s/ Yifat Zommer
|
|
|
Yifat Zommer
|
|||
|
Chief Financial Officer
|
|||
|
(principal financial and accounting officer)
|
|||
10
TABLE OF CONTENTS
Part I Financial InformationItem 1 - Financial StatementsNote 1 - Significant Accounting Policies:Note 1 - Significant Accounting Policies (continued):Note 1 - Significant Accounting PoliciesNote 2 - Commitments:Note 2 - Commitments (continued):Note 2 - CommitmentsNote 3 - Fair Value:Note 4 - Marketable Securities:Note 4 - Marketable Securities (continued):Note 4 - Marketable SecuritiesNote 5 - Stock Holders Equity:Note 6 - Stock Based Compensation:Note 6 - Stock Based Compensation (continued):Note 6 - Stock Based CompensationNote 7 - Related Parties Transactions:Note 7 - Related Parties Transactions (continued):Note 7 - Related Parties TransactionsNote 8 Subsequent EventNote 8 Subsequent EvenItem 2 - Management S Discussion and Analysis Of Financial Condition and Results Of OperationsItem 3 Quantitative and Qualitative Disclosures About Market RiskItem 4 - Controls and ProceduresPart II Other InformationItem 6 - Exhibits